Kingsview Wealth Management LLC Lowers Holdings in DexCom, Inc. (NASDAQ:DXCM)

Kingsview Wealth Management LLC lowered its holdings in DexCom, Inc. (NASDAQ:DXCM) by 45.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,819 shares of the medical device company’s stock after selling 2,303 shares during the quarter. Kingsview Wealth Management LLC’s holdings in DexCom were worth $219,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in DXCM. Crossmark Global Holdings Inc. boosted its position in shares of DexCom by 1.0% during the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after buying an additional 182 shares during the period. GPS Wealth Strategies Group LLC boosted its holdings in DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after acquiring an additional 185 shares during the period. Magnolia Capital Advisors LLC boosted its holdings in DexCom by 2.6% during the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock valued at $638,000 after acquiring an additional 210 shares during the period. Riverview Trust Co boosted its holdings in DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its stake in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Buying and Selling

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the sale, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock worth $3,628,069 in the last quarter. 0.30% of the stock is owned by insiders.

Analyst Ratings Changes

Several research firms have recently commented on DXCM. JPMorgan Chase & Co. raised their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Friday, October 25th. Leerink Partners decreased their price target on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Royal Bank of Canada cut their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Robert W. Baird upgraded DexCom from a “neutral” rating to an “outperform” rating and lifted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Citigroup lifted their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Trading Up 5.9 %

NASDAQ DXCM opened at $89.07 on Friday. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. The firm’s fifty day moving average price is $82.44 and its 200 day moving average price is $75.44. The company has a market capitalization of $34.79 billion, a price-to-earnings ratio of 53.34, a price-to-earnings-growth ratio of 2.26 and a beta of 1.14. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 31.40% and a net margin of 17.22%. On average, sell-side analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.